When it comes to antidepressant drug trial reporting,makers literally have been accentuating the positive, according to a newanalysis. 

The study reviewed 74 antidepressant trials involving 12drugs between 1987 and 2004. Researchers found that 94% of positive studies -studies that supported the effectiveness of antidepressants such as Prozac andZoloft – were published, compared with only 14% of less flattering reports.

Selective reporting of favorable studies ultimately maylead to disappointment for patients, said Dr. Erick H. Turner, a psychiatristand former Food & Drug Administration reviewer. The study was a jointeffort between researchers at the Oregon Health and Sciences University, KentState University and the University of California, Riverside.